Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CEFTAROLINE FOSAMIL vs CEFIXIME
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: June 2026 · OpiCalc Medical Review Team
Ceftaroline fosamil is a prodrug that is converted to the active metabolite ceftaroline. Ceftaroline inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), including PBP2a in MRSA and PBP2x in Streptococcus pneumoniae, thereby preventing cross-linking of peptidoglycan.
Cefixime is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
Acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible organisms, including MRSA,Community-acquired bacterial pneumonia (CABP) caused by susceptible organisms
FDA-approved: Uncomplicated urinary tract infections, otitis media, pharyngitis/tonsillitis, acute exacerbations of chronic bronchitis, uncomplicated gonorrhea.,Off-label: Typhoid fever, shigellosis, Lyme disease, prophylaxis for bacterial endocarditis.
600 mg IV every 12 hours infused over 1 hour
400 mg orally once daily or 200 mg orally every 12 hours for 7–14 days; uncomplicated gonorrhea: 400 mg orally as a single dose
Terminal elimination half-life is approximately 2.6 hours in patients with normal renal function. This supports twice-daily dosing in most infections.
Terminal elimination half-life is 3-4 hours in patients with normal renal function; extends to 11-15 hours in moderate renal impairment (Cr Cl 20-40 m L/min) and up to 20 hours in severe impairment.
Cr Cl 30-50 m L/min: 400 mg IV every 12 hours; Cr Cl 15-29 m L/min: 300 mg IV every 12 hours; Cr Cl <15 m L/min or hemodialysis: 200 mg IV every 12 hours
Cr Cl 30–59 m L/min: 300 mg orally once daily; Cr Cl 15–29 m L/min: 200 mg orally once daily; Cr Cl <15 m L/min or hemodialysis: 200 mg orally once daily
No FDA black box warning.
Ceftaroline fosamil is a cephalosporin antibiotic classified as FDA Pregnancy Category B. Animal reproduction studies have not demonstrated fetal harm, but no adequate and well-controlled studies exist in pregnant women. There is no evidence of teratogenicity in first trimester. Risk cannot be ruled out; use only if clearly needed.
FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data; no increased risk of major malformations reported. Caution in first trimester due to lack of robust data.
Ceftaroline fosamil, a fifth-generation cephalosporin, has activity against MRSA due to its affinity for PBP2a. It is also active against many Gram-negative pathogens including Enterobacteriaceae but not ESBL-producing strains. Note that it does not cover Pseudomonas aeruginosa. It is used for community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI). Like other beta-lactams, it is time-dependent and requires prolonged infusion for optimal pharmacokinetic/pharmacodynamic target attainment (e.g., over 2 hours). It may cause false-positive Coombs test (direct antiglobulin test) and rarely immune-mediated hemolytic anemia. Adjust dose in renal impairment (Cr Cl ≤50 m L/min).
Cefixime is an oral third-generation cephalosporin with activity against Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, Neisseria gonorrhoeae, and many Enterobacteriaceae. It is not active against Pseudomonas aeruginosa, Enterococcus, or methicillin-resistant Staphylococcus aureus. Use for uncomplicated gonorrhea as a single 400 mg oral dose. Monitor for hypersensitivity reactions, especially in penicillin-allergic patients (cross-reactivity ~10%). Dose adjustment required for Cr Cl <30 m L/min (maximum 300 mg/day). Avoid in patients with cephalosporin or severe penicillin allergy. Can cause false-positive Coombs test and urinary glucose tests using copper reduction (e.g., Clinitest).
No interactions on record
Common clinical questions about CEFTAROLINE FOSAMIL vs CEFIXIME, answered by our medical review team.
CEFTAROLINE FOSAMIL is a Cephalosporin Antibiotic that works by Ceftaroline fosamil is a prodrug that is converted to the active metabolite ceftaroline. Ceftaroline inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), including PBP2a in MRSA and PBP2x in Streptococcus pneumoniae, thereby preventing cross-linking of peptidoglycan.. CEFIXIME is a Cephalosporin Antibiotic that works by Cefixime is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CEFTAROLINE FOSAMIL and CEFIXIME depend on the specific clinical indication. These are both Cephalosporin Antibiotic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CEFTAROLINE FOSAMIL is: 600 mg IV every 12 hours infused over 1 hour. The standard adult dose of CEFIXIME is: 400 mg orally once daily or 200 mg orally every 12 hours for 7–14 days; uncomplicated gonorrhea: 400 mg orally as a single dose. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CEFTAROLINE FOSAMIL and CEFIXIME in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CEFTAROLINE FOSAMIL is classified as Category A/B. Ceftaroline fosamil is a cephalosporin antibiotic classified as FDA Pregnancy Category B. Animal reproduction studies have not demonstrated fetal harm, but no adequate and well-con. CEFIXIME is classified as Category A/B. FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data; no increased risk of major malformations reported. Caution in first trimester due to . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.
Ceftaroline fosamil is metabolized by plasma phosphatases to active ceftaroline. Ceftaroline is minimally metabolized by the liver and undergoes renal elimination predominantly as unchanged drug.
Cefixime is not significantly metabolized; it is primarily excreted unchanged in the urine and bile.
Renal excretion of unchanged ceftaroline accounts for approximately 88% of the administered dose. Biliary/fecal elimination is minimal (<6%).
Renal excretion of unchanged drug accounts for 50-60% of elimination; biliary/fecal elimination accounts for 10-20%.
Approximately 20% bound to plasma proteins, primarily albumin.
Approximately 65-70% bound primarily to albumin.
Volume of distribution is approximately 0.38 L/kg, indicating distribution primarily into extracellular fluid.
Volume of distribution is 0.3-0.5 L/kg, indicating distribution primarily into extracellular fluid.
Only administered intravenously; bioavailability is 100% by the IV route.
Oral suspension: 40-50%; tablets: 40-50% (fasting) but increased to 50-60% with food.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B); not studied in severe impairment (Child-Pugh C)
Mild to moderate hepatic impairment (Child-Pugh A or B): no adjustment necessary; severe hepatic impairment (Child-Pugh C): limited data, use with caution
For ages 2 months to <18 years: 12 mg/kg/dose IV every 8 hours (max 600 mg/dose) infused over 1 hour
Children ≥6 months: 8 mg/kg/day orally divided every 12–24 hours; maximum 400 mg/day; for pharyngitis/tonsillitis: 8 mg/kg/day as a single dose or divided every 12 hours for 10 days
No specific dose adjustment based on age alone; adjust based on renal function as per renal adjustment guidelines
No specific dose adjustment; monitor renal function; use lowest effective dose due to potential age-related renal decline
No FDA black box warnings.
No specific food interactions. However, avoid alcohol ingestion in cases of liver dysfunction or if other interacting drugs are used. No restrictions on diet.
Take cefixime with or without food; food does not affect absorption. Avoid alcohol during therapy as it may exacerbate gastrointestinal side effects or cause disulfiram-like reaction (rare with cephalosporins). Maintain adequate fluid intake to prevent crystalluria.
Ceftaroline is excreted into human breast milk in low concentrations. The milk-to-plasma (M/P) ratio is not established. Based on limited data, it is considered compatible with breastfeeding due to poor oral bioavailability and minimal GI absorption in infants. However, caution is advised, and monitor infant for diarrhea or allergic reactions.
Cefixime is excreted into human milk in low concentrations. M/P ratio not established. Considered compatible with breastfeeding due to minimal oral bioavailability in infants; monitor for diarrhea and rash.
No specific dose adjustments are recommended for pregnancy. Physiological changes in pregnancy (e.g., increased volume of distribution, enhanced renal clearance) may lower serum concentrations; however, current data do not support routine dose modification. Monitor clinical response and consider therapeutic drug monitoring if available.
No dose adjustment required for pregnancy alone. However, due to increased renal clearance during pregnancy, consider monitoring clinical response; no standard dose increase recommended.
Take this medication exactly as prescribed; it is given intravenously by a healthcare provider.,Tell your doctor if you have a history of allergies to penicillins, cephalosporins, or other beta-lactams.,Report any signs of allergic reaction such as rash, hives, difficulty breathing, or swelling of the face/throat.,Notify your healthcare provider if you experience severe diarrhea, especially if watery or bloody, as this may indicate Clostridioides difficile infection.,Inform your doctor if you have kidney problems, as dose adjustments may be necessary.,Keep all appointments for blood tests to monitor kidney function and blood cell counts.
Take exactly as prescribed; complete the full course even if you feel better to prevent bacterial resistance.,For gonorrhea, a single dose is usually effective; you may need a follow-up test to confirm cure.,This medication may cause diarrhea; contact your doctor if it becomes severe, watery, or bloody.,If you experience rash, hives, difficulty breathing, or swelling of face/tongue/throat, seek emergency medical attention.,Do not breastfeed without consulting your doctor, as cefixime passes into breast milk.,Inform your doctor if you have a history of penicillin allergy, kidney disease, or colitis.,Cefixime may cause false-positive results on certain urine glucose tests; use glucose oxidase methods (e.g., Clinistix) instead.